Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This study seeks to examine the investigational use of the conditioning regimen
(bendamustine, fludarabine, and rituximab) prior to haploidentical peripheral blood
allogeneic stem cell transplantation with Post-Transplant Cyclophosphamide. The study will
also test the investigational use of CD56-enriched Donor Lymphocyte Infusion to see if this
treatment is safe, and whether or not it will help patients achieve better outcomes
post-transplant, including reduced risk of Graft-Versus-Host Disease (GVHD), and preventing
disease relapse.